SWAN-iCARE
Smart wearable and autonomous negative pressure device for wound monitoring and therapy
| Coordinatore | EXODUS ANONYMOS ETAIREIA PLIROFORIKIS
Organization address
address: ESTIAS 1 & MESOGEION 73-75 contact info |
| Nazionalità Coordinatore | Greece [EL] |
| Totale costo | 8˙079˙179 € |
| EC contributo | 6˙113˙999 € |
| Programma | FP7-ICT
Specific Programme "Cooperation": Information and communication technologies |
| Code Call | FP7-ICT-2011-8 |
| Funding Scheme | CP |
| Anno di inizio | 2012 |
| Periodo (anno-mese-giorno) | 2012-09-01 - 2016-08-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
EXODUS ANONYMOS ETAIREIA PLIROFORIKIS
Organization address
address: ESTIAS 1 & MESOGEION 73-75 contact info |
EL (ATHINA) | coordinator | 0.00 |
| 2 |
CAP PARTNER APS, EWMA SECRETARIAT DFSG SECRETARIAT
Organization address
address: NORDRE FASANVEJ 113-115 contact info |
DK (FREDERIKSBERG) | participant | 0.00 |
| 3 |
CENTRE HOSPITALIER UNIVERSITAIRE DE GRENOBLE
Organization address
address: BOULEVARD DE LA CHANTOURNE contact info |
FR (LA TRONCHE) | participant | 0.00 |
| 4 |
COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES
Organization address
address: RUE LEBLANC 25 contact info |
FR (PARIS 15) | participant | 0.00 |
| 5 |
CSEM CENTRE SUISSE D'ELECTRONIQUE ET DE MICROTECHNIQUE SA - RECHERCHE ET DEVELOPPEMENT
Organization address
address: RUE JAQUET DROZ 1 contact info |
CH (NEUCHATEL) | participant | 0.00 |
| 6 |
EURORESEARCH SRL
Organization address
address: VIALE DEI MILLE 20 contact info |
IT (MILANO) | participant | 0.00 |
| 7 |
HAEMOPHARM BIOFLUIDS SRL
Organization address
address: VIA LARGA 2 contact info |
IT (MILANO) | participant | 0.00 |
| 8 |
INSTITUTE OF COMMUNICATION AND COMPUTER SYSTEMS
Organization address
address: Patission Str. 42 contact info |
EL (ATHINA) | participant | 0.00 |
| 9 |
SMITH & NEPHEW MEDICAL LIMITED
Organization address
address: HESSLE ROAD 101 contact info |
UK (HULL) | participant | 0.00 |
| 10 |
SWISSINNOV PRODUCT SARL
Organization address
address: RUE DE L'ETRAZ 1 contact info |
CH (GLAND) | participant | 0.00 |
| 11 |
UNIVERSITA DI PISA
Organization address
address: Lungarno Pacinotti 43/44 contact info |
IT (PISA) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
SWAN-iCARE is an ambitious project aiming at developing an integrated autonomous device for the monitoring and the personalized management of chronic wounds, mainly diabetic foot ulcers and venous leg ulcers. Most foot and leg ulcers are caused by diabetes and vascular problems respectively but a remarkable number of them is also due to the co-mordibity influence of many other diseases (e.g. kidney disease, congestive heart failure, high blood pressure, inflammatory Bowel disease). More than 10 million in Europe suffer from chronic wounds, a number of which is expected to grow due to the aging of the population.
Core of the project is the fabrication of a conceptually new wearable negative pressure device equipped with Information and Communication Technologies. Such device will allow to:•taccurately monitor many wound parameters via non-invasive integrated micro-sensors;•tearly identify infections;•tprovide remotely an innovative personalised two-line therapy via non-invasive micro-actuators to supplement the negative pressure wound therapy.
SWAN-iCARE novel idea focuses on the provision of pioneering two-line therapy at home: a first line based on a negative pressure device, a second line based on the integrated micro-actuators.
The physician's analysis of the collected data will be the basis for the decision and the remote control of the therapy. The closed-loop approach offered by SWAN-iCARE project provides unprecedented levels of care, improves patient's health condition and significantly lowers costs and need for hospitalisation, with obvious advantages for both patients and health care services.
The project follows an iterative validation approach which includes a series of test session in-vitro on human biological samples and in-vivo on humans.
A detailed impact analysis and business plan wil be conducted towards the successful commercialisation of the project results.